FDA Slaps Bi-Coastal Pharma for Complaint Handling, QA Problems

The FDA has sent New Jersey-based Bi-Coastal Pharma International a warning letter, insisting that the company complete a complaint investigation rather than passing the buck to its now-defunct supplier.
Source: Drug Industry Daily